217 related articles for article (PubMed ID: 24928706)
1. Etanercept therapy for toxic epidermal necrolysis.
Paradisi A; Abeni D; Bergamo F; Ricci F; Didona D; Didona B
J Am Acad Dermatol; 2014 Aug; 71(2):278-83. PubMed ID: 24928706
[TBL] [Abstract][Full Text] [Related]
2. A new case series on etanercept treatment for toxic epidermal necrolysis.
Paradisi A; Abeni D; Didona D; Ricci F; Canzona F; Didona B
Eur J Dermatol; 2020 Oct; 30(5):561-568. PubMed ID: 33021477
[TBL] [Abstract][Full Text] [Related]
3. Toxic epidermal necrolysis successfully treated with etanercept.
Gubinelli E; Canzona F; Tonanzi T; Raskovic D; Didona B
J Dermatol; 2009 Mar; 36(3):150-3. PubMed ID: 19335689
[TBL] [Abstract][Full Text] [Related]
4. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases.
Napolitano M; Giampetruzzi AR; Didona D; Papi M; Didona B
J Am Acad Dermatol; 2013 Dec; 69(6):e303-5. PubMed ID: 24238188
[No Abstract] [Full Text] [Related]
5. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
6. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
Tan SK; Tay YK
Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
[TBL] [Abstract][Full Text] [Related]
8. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
Chen J; Wang B; Zeng Y; Xu H
Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.
Kardaun SH; Jonkman MF
Acta Derm Venereol; 2007; 87(2):144-8. PubMed ID: 17340021
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of histologic features of toxic epidermal necrolysis.
Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
[TBL] [Abstract][Full Text] [Related]
11. Use of Etanercept in a Series of Pediatric Patients With Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Spectrum Disease.
Eliades P; Fonseca M; Harp J
JAMA Dermatol; 2020 Aug; 156(8):921-922. PubMed ID: 32347889
[No Abstract] [Full Text] [Related]
12. The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential.
So N; Leavitt E; Aleshin M; Worswick S
Dermatol Ther; 2018 Sep; 31(5):e12684. PubMed ID: 30175438
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
14. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series.
Esposito M; Mazzotta A; Casciello C; Chimenti S
Dermatology; 2008; 216(4):355-60. PubMed ID: 18285687
[TBL] [Abstract][Full Text] [Related]
15. Survival rate of etanercept for psoriasis in real life: a multicentre observational study.
Herrera-Acosta E; Suárez-Pérez JA; Aguilera J; Gómez-García F; Jiménez-Puya R; Guimerá F; Mendiola MV; Herrera-Ceballos E
Eur J Dermatol; 2014; 24(5):619-20. PubMed ID: 25115194
[No Abstract] [Full Text] [Related]
16. Parapharyngeal abscess in a patient receiving etanercept.
Borrás-Blasco J; Nuñez-Cornejo C; Gracia-Perez A; Rosique-Robles JD; Casterá MD; Viosca E; Abad FJ
Ann Pharmacother; 2007 Feb; 41(2):341-4. PubMed ID: 17227824
[TBL] [Abstract][Full Text] [Related]
17. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
Leonardi C; Strober B; Gottlieb AB; Elewski BE; Ortonne JP; van de Kerkhof P; Chiou CF; Dunn M; Jahreis A
J Drugs Dermatol; 2010 Aug; 9(8):928-37. PubMed ID: 20684143
[TBL] [Abstract][Full Text] [Related]
19. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers.
Hirahara K; Kano Y; Sato Y; Horie C; Okazaki A; Ishida T; Aoyama Y; Shiohara T
J Am Acad Dermatol; 2013 Sep; 69(3):496-8. PubMed ID: 23957982
[No Abstract] [Full Text] [Related]
20. Use of granulocyte colony-stimulating factor in the treatment of toxic epidermal necrolysis--experience with 3 patients.
Mahajan R; Kanwar AJ
Skinmed; 2013; 11(5):269-71. PubMed ID: 24340465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
